The Larger World ArchiveClaims · Sources · Evidence
Earth, geology and hidden geographyLive debateCancer biology · 1977 – present

Peto's Paradox

A blue whale has a thousand times more cells than you. By the arithmetic of random mutation, it should die of cancer almost immediately. It lives a century.

An African elephant. Elephants carry about twenty copies of the TP53 tumour suppressor, an
An African elephant. Elephants carry about twenty copies of the TP53 tumour suppressor, and get cancer less often than their cell count predicts. Image: Charles J. Sharp · CC BY-SA 4.0 — Wikimedia Commons.

The paradox

Richard Peto noted in 1977 that cancer risk across species does not scale with body size or lifespan. If every cell has some chance of becoming malignant, a large, long-lived animal should accumulate far more tumours.

The observation has held up: elephants and whales have cancer rates comparable to or lower than humans, despite vastly more cell divisions and decades more exposure.

The proposed answers

More tumour suppressors. Elephants have around 20 copies of TP53, the 'guardian of the genome', against our two. Cells with damaged DNA are killed more readily — a mechanism demonstrated in elephant cells in culture.

Slower metabolism per cell. Large animals have lower mass-specific metabolic rates, which may mean less oxidative damage per cell.

Cell-size and division-rate differences. Whale cells are not proportionally bigger, but their division dynamics may differ.

Evolutionary tuning. Species with large bodies and long lives may have been selected for stronger cancer suppression, because the alternative is extinction.

Why it is not settled

The data are thin. Cancer prevalence in wild cetaceans is hard to measure: they are rarely necropsied systematically, and many die of other causes before cancer would appear. The low rates may be partly ascertainment.

TP53 copy number is not the whole story. Elephants are not cancer-proof; they still get tumours. And some large, long-lived species do not have extra TP53.

The mechanism might be general rather than special. Better DNA repair, tighter cell-cycle checkpoints, and immune surveillance could all contribute without any single trick.

Why it matters

Because if large animals have evolved better cancer suppression, the mechanisms are potential drug targets. Comparative oncology is now a real field, and the elephant TP53 result is its founding observation.

It is also a clean example of the archive's method: a real paradox, several plausible mechanisms, and a lot of popular writing that presents one of them as the answer.

Sources for this page

  • Wikipedia, “Peto's paradox” — statement and proposed mechanismsen.wikipedia.org
  • Abrégé et al. (2015), TP53 retrogenes and cancer resistance in elephantsjamanetwork.com
  • Caulin & Maley (2011), Peto's paradox and the evolution of cancer suppressiononlinelibrary.wiley.com
  • U.S. National Cancer Institute, comparative oncologywww.cancer.gov